**Briciclib**

**Cat. No.:** HY-16366  
**CAS No.:** 865783-99-9  
**Molecular Formula:** $C_{19}H_{23}O_{10}PS$  
**Molecular Weight:** 474.42  
**Target:** Eukaryotic Initiation Factor (eIF); Autophagy  
**Pathway:** Cell Cycle/DNA Damage; Autophagy  
**Storage:**  
- Powder: -20°C 3 years  
- Powder: 4°C 2 years  
- In solvent: -80°C 6 months  
- In solvent: -20°C 1 month

**SOLVENT & SOLUBILITY**

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>DMSO: $\geq$ 31 mg/mL (65.34 mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Concentration</strong></td>
<td><strong>Mass</strong></td>
</tr>
</tbody>
</table>
| 1 mM                      | 2.1078 mL  
| 5 mM                      | 10.5392 mL  
| 10 mM                     | 21.0784 mL |

*“$\geq$” means soluble, but saturation unknown.*

Please refer to the solubility information to select the appropriate solvent.

**BIOLOGICAL ACTIVITY**

**Description**  
Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.

**IC$_{50}$ & Target**  
eIF4E$^{[1]}$

**In Vitro**  
Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI$_{50}$s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours$^{[1]}$.

**REFERENCES**

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909
E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA